Search results
Results From The WOW.Com Content Network
As I discussed in my last article on Cassava Sciences (NASDAQ:SAVA), controversy continues to weigh on the performance of SAVA stock. Over the past week, shares in the clinical-stage biotech firm ...
Cassava Sciences (NASDAQ:SAVA) stands to gain a good deal this year. This will all depend on the company’s Phase 3 clinical trials progress in the results on actual patients with Alzheimer’s ...
Early in October, I said that Cassava Sciences’ (NASDAQ:SAVA) big gains in late September had investors dreaming of a big payday for SAVA stock in 2022. Source: Pavel Kapysh / Shutterstock.com I ...
Sometimes, it’s hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ:SAVA). As the ...
Cassava Sciences (NASDAQ:SAVA) stock took off once again during September. Rumors about the Securities and Exchange Commission (or SEC) clearing its investigation of the scandal-tarnished biotech ...
Yet while SAVA stock has been acting less wild, don’t blame it on a lack of new developments. As InvestorPlace’s Eddie Pan reported Oct. 13, the biotech firm has announced plans to hold an ...
If volatility is not your bag, then definitely stay away from Cassava Sciences (SAVA) stock. This biotech has been one of 2021’s most volatile, not to mention, controversial names. Ultimately ...
Six months ago Cassava Sciences (SAVA) had a problem. A citizen petition was logged with the FDA calling for a halt on the company's simufilam drug for the treatment of Alzheimer's Disease. The ...